Alterity Therapeutics Limited (ATHE)

NASDAQ: ATHE · USD

$2.52

+0.05 (+2.0%)· Recorded snapshot

Market cap	47.2M
Revenue (ttm)	2.5M
Net income (ttm)	-16.2M
EPS (ttm)	-$0.94
Shares out	218.5M
Volume	116,610
Beta	-0.01

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.5M
Net income (ttm): -16.2M
EPS (ttm): -$0.94
Market cap: 47.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 20:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-55

P25 n/aP50 n/aP75 n/a

ROIC-36.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ATHE indicators

Market & fundamental data

Available fields

211

Groups with data

Currency

AUD

Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001131343
Company name	Alterity Therapeutics Limited
Country	Australia
Country code	US
CUSIP number	02155X205
Earnings date	2026-11-04
Employees	11
Employees change	2
Employees growth	22.22%
Enterprise value	$21.4M
Exchange	NASDAQ
Financial currency	AUD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	June
Founded	1997
Industry	Biotechnology
Is primary listing	No
Is SPAC	No
ISIN number	US02155X2053
Last 10-K release date	2026-08-28
Last earnings date	2026-02-25
Last refreshed	2026-11-04
Last stock split date	2023-01-09
Last stock split type	Reverse
Market cap	$47.2M
Market cap category	Nano-Cap
Next earnings date	2026-11-04
Options	No
Price	$2.52
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-04
Symbol	ATHE
Website	https://alteritytx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-37.14%
EV/Sales	8.18x
FCF / EV yield	-77.34%
FCF yield	-34.13%
Forward EV/Sales	32.64x
Forward P/S	73.99x
P/B ratio	1.57x
P/S ratio	18.54x
Price / tangible book value	1.57x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	92.72%
Operating margin	-695.13%
Pretax margin	-645.08%
Profit per employee	$-1.5M
Revenue per employee	$227,038
ROA	-34.08%
ROA (5Y)	-33.46%
ROCE	-58.54%
ROE	-54.98%
ROE (5Y)	-57.8%
ROIC	-36.7%
SBC / revenue	124.46%
Tax / revenue	3.14%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	-36.98%
Gross profit growth (Q)	-67.89%
Gross profit growth 3Y	-2.68%
Gross profit growth 5Y	-3.4%
Net income growth years	0
Revenue growth	-33.63%
Revenue growth (Q)	-78.96%
Revenue growth (QoQ)	-71.23%
Revenue growth 10Y	-3%
Revenue growth 3Y	-2.68%
Revenue growth 5Y	-3.61%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-5,613
Depreciation and amortization	$2,488
EBIT	$-17.4M
EBITDA	$-17.4M
EPS	$-0.94
FCF per share	$-0.07
Financing cash flow	$13.2M
Free cash flow	$-15.8M
Free cash flow minus SBC	$-19M
Gross profit	$2.3M
Income taxes	$78,519
Investing cash flow	$5.2M
Net borrowing	$-95,811
Net cash flow	$2.9M
Net income	$-16.2M
Operating cash flow minus SBC	$-19M
Operating income	$-17.4M
Revenue	$2.5M
Stock-based compensation	$3.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	11
Book value per share	$0.14
Debt / equity	0
Long-term assets	$-317,500
Long-term liabilities	$64,724
Net cash (debt)	$25.7M
Net cash / market cap	55.46%
Net cash growth	197.48%
Net debt / equity	-0.87
Piotroski F-Score	2
Property, plant and equipment	$133,699
Shareholders' equity	$29.6M
Tangible book value	$29.6M
Tangible book value per share	$0.14
Total assets	$31.8M
Total cash	$25.8M
Total debt	$133,840
Total liabilities	$2.3M
WACC	4.21%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.08
Current assets	$32.2M
Current liabilities	$2.2M
Current ratio	14.52
Net working capital	$3.7M
Quick ratio	14.26
Working capital	$29.5M
Working capital turnover	0.09

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-64.53%
Dividend yield	0%
Shareholder yield	-64.53%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-89.32%
10Y return CAGR	-20.05%
10Y total return	-89.32%
150-day SMA	$4.15
15Y price change	-97.2%
15Y return CAGR	-21.21%
15Y total return	-97.2%
1D price change	2.02%
1M price change	-26.96%
1M total return	-26.96%
1W price change	16.13%
1W total return	16.13%
1Y price change	-37.47%
1Y return CAGR	-37.49%
1Y total return	-37.47%
20-day SMA	$2.47
200-day SMA	$3.97
20Y price change	-98.6%
20Y return CAGR	-19.23%
20Y total return	-98.6%
3M price change	-43.46%
3M total return	-43.46%
3Y price change	5%
3Y return CAGR	1.64%
3Y total return	5%
50-day SMA	$3.36
50-day SMA vs 200-day SMA	50under200
52-week high	$5.89
52-week high date	2026-07-06
52-week low	$2.01
52-week low date	2026-10-26
5Y price change	-79.68%
5Y return CAGR	-27.29%
5Y total return	-79.68%
6M price change	-46.67%
6M total return	-46.67%
After-hours change	4.45%
After-hours close	$2.47
After-hours price	$2.58
All-time high	$797.40
All-time high date	2014-01-30
All-time low	$1.00
All-time low date	2024-11-22
Average true range (ATR)	$0.32
Average volume	231.3K
Beta (5Y)	-0.01
Change from 52-week high	-57.23%
Change from 52-week low	25.37%
Change from all-time high	-99.68%
Change from all-time low	151.75%
Change from open	2.02%
Day's gap	0%
Dollar volume	$293,857
High price	$2.65
Low price	$2.37
Monthly RSI	42.87
Open price	$2.47
Position in 52-week range	53.57%
Premarket change	2.02%
Premarket close	$2.47
Premarket price	$2.52
Premarket volume	5.9K
Previous close	$2.47
Price vs 150-day SMA	-39.28%
Price vs 20-day SMA	2.02%
Price vs 200-day SMA	-36.44%
Price vs 50-day SMA	-25.07%
Relative volume	0.5
RSI	43.73
Sharpe ratio	-0.4
Sharpe ratio (3Y)	0.44
Sharpe ratio (5Y)	0.07
Sortino ratio	-0.51
Sortino ratio (3Y)	1.06
Sortino ratio (5Y)	0.23
Volume	116.6K
Weekly RSI	34.94
YTD price change	-18.18%
YTD total return	-18.18%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	181.5M
Float percentage	83.08%
Shares change (QoQ)	6.78%
Shares change (YoY)	64.53%
Shares held by insiders	3.06%
Shares held by institutions	32.82%
Shares outstanding	218.5M
Short % of shares	0.2%
Short ratio	1.7 days

Deeper analysis on ATHE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ATHE report

Is a complete ATHE research report available?

No complete published report is available for Alterity Therapeutics Limited (ATHE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Alterity Therapeutics Limited (ATHE)

Price

Financial snapshot

Fair-value bridge

Latest news · ATHE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ATHE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ATHE

Frequently asked questions